Clinical Trial Update: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study results for a combination regimen of Brentuximab Vedotin with Ifosfamide, Carboplatin, and Etoposide in relapsed or refractory Hodgkin lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-09